Tags

Type your tag names separated by a space and hit enter

Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
J Diabetes Complications. 2007 Mar-Apr; 21(2):118-23.JD

Abstract

OBJECTIVES

Metformin is widely used in patients with type 2 diabetes but may decrease vitamin B(12) levels and increase levels of homocysteine (Hcy), a cardiovascular risk factor. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, may reduce markers of inflammation. We investigated whether 6 weeks' treatment with metformin or rosiglitazone affects serum concentrations of Hcy, folate, or vitamin B(12) in subjects with newly diagnosed type 2 diabetes compared with controls.

METHODS

We examined 165 patients with type 2 diabetes. Fasting blood samples, a physical examination, and a complete medical history were performed at the beginning and at the end of the treatment. All blood samples were obtained after a 12-h fast.

RESULTS

After treatment, metformin use was associated with an increase in levels of Hcy by 2.36 micromol/l and decreases in folate and vitamin B(12) concentrations by -1.04 ng/ml and -20.17 pg/ml. During rosiglitazone treatment, Hcy levels decreased by -0.92 micromol/l; folate and vitamin B(12) levels remained unchanged. Metformin and rosiglitazone significantly decreased levels of triglyceride (TG), low-density lipoprotein (LDL), total cholesterol (total-C), HbA1c, insulin, and homeostasis model assessment (HOMA). Metformin also significantly decreased body weight. In controls, there was no change in Hcy, folic acid, vitamin B(12), TG, LDL, total-C, HbA1c, insulin, or HOMA levels. Homocysteine change did not correlate with insulin, folate, or vitamin B(12) changes in the metformin and rosiglitazone groups.

CONCLUSIONS

In patients with type 2 diabetes, metformin reduces levels of folate and vitamin B(12) and increases Hcy. Conversely, rosiglitazone decreases Hcy levels in this time period. The clinical significance of these findings remains to be investigated.

Authors+Show Affiliations

Department of Endocrinology and Metabolic Diseases, Baskent University Faculty of Medicine, Ankara, Turkey. drsahinmustafa@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17331860

Citation

Sahin, Mustafa, et al. "Effects of Metformin or Rosiglitazone On Serum Concentrations of Homocysteine, Folate, and Vitamin B12 in Patients With Type 2 Diabetes Mellitus." Journal of Diabetes and Its Complications, vol. 21, no. 2, 2007, pp. 118-23.
Sahin M, Tutuncu NB, Ertugrul D, et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications. 2007;21(2):118-23.
Sahin, M., Tutuncu, N. B., Ertugrul, D., Tanaci, N., & Guvener, N. D. (2007). Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 21(2), 118-23.
Sahin M, et al. Effects of Metformin or Rosiglitazone On Serum Concentrations of Homocysteine, Folate, and Vitamin B12 in Patients With Type 2 Diabetes Mellitus. J Diabetes Complications. 2007 Mar-Apr;21(2):118-23. PubMed PMID: 17331860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. AU - Sahin,Mustafa, AU - Tutuncu,Neslihan B, AU - Ertugrul,Derun, AU - Tanaci,Nedret, AU - Guvener,Nilgun D, PY - 2005/06/30/received PY - 2005/09/16/revised PY - 2005/10/20/accepted PY - 2007/3/3/pubmed PY - 2007/7/6/medline PY - 2007/3/3/entrez SP - 118 EP - 23 JF - Journal of diabetes and its complications JO - J Diabetes Complications VL - 21 IS - 2 N2 - OBJECTIVES: Metformin is widely used in patients with type 2 diabetes but may decrease vitamin B(12) levels and increase levels of homocysteine (Hcy), a cardiovascular risk factor. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, may reduce markers of inflammation. We investigated whether 6 weeks' treatment with metformin or rosiglitazone affects serum concentrations of Hcy, folate, or vitamin B(12) in subjects with newly diagnosed type 2 diabetes compared with controls. METHODS: We examined 165 patients with type 2 diabetes. Fasting blood samples, a physical examination, and a complete medical history were performed at the beginning and at the end of the treatment. All blood samples were obtained after a 12-h fast. RESULTS: After treatment, metformin use was associated with an increase in levels of Hcy by 2.36 micromol/l and decreases in folate and vitamin B(12) concentrations by -1.04 ng/ml and -20.17 pg/ml. During rosiglitazone treatment, Hcy levels decreased by -0.92 micromol/l; folate and vitamin B(12) levels remained unchanged. Metformin and rosiglitazone significantly decreased levels of triglyceride (TG), low-density lipoprotein (LDL), total cholesterol (total-C), HbA1c, insulin, and homeostasis model assessment (HOMA). Metformin also significantly decreased body weight. In controls, there was no change in Hcy, folic acid, vitamin B(12), TG, LDL, total-C, HbA1c, insulin, or HOMA levels. Homocysteine change did not correlate with insulin, folate, or vitamin B(12) changes in the metformin and rosiglitazone groups. CONCLUSIONS: In patients with type 2 diabetes, metformin reduces levels of folate and vitamin B(12) and increases Hcy. Conversely, rosiglitazone decreases Hcy levels in this time period. The clinical significance of these findings remains to be investigated. SN - 1056-8727 UR - https://www.unboundmedicine.com/medline/citation/17331860/Effects_of_metformin_or_rosiglitazone_on_serum_concentrations_of_homocysteine_folate_and_vitamin_B12_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8727(05)00144-3 DB - PRIME DP - Unbound Medicine ER -